Expert opinions on influenza vaccination for patients with common cardiovascular diseases.
10.3760/cma.j.cn112138-20240719-00462
- Collective Name:National Cardiovascular Disease Quality Initiative (CDQI) Heart Failure Expert Panel
- Publication Type:Journal Article
- MeSH:
Humans;
Cardiovascular Diseases/prevention & control*;
Influenza Vaccines/administration & dosage*;
Influenza, Human/prevention & control*;
Vaccination;
Expert Testimony
- From:
Chinese Journal of Internal Medicine
2025;64(1):11-22
- CountryChina
- Language:Chinese
-
Abstract:
The influenza virus is classified as a single-stranded negative-sense RNA virus in Orthomyxoviridae family, with epidemiological properties distinct from common cold. Previous studies have found that influenza infection can cause cardiac damage through various pathways, and patients with cardiovascular diseases are at relatively higher risk of adverse disease outcomes. Influenza vaccination has been proven to provide protective effect on patients with cardiovascular diseases. Currently, there is insufficient emphasis placed by cardiologists and cardiovascular disease patients on the prevention of influenza infection, leading to a low influenza vaccination rate in China. Therefore, based on the current clinical research progress and relevant guidelines, combined with the safety, feasibility and health economic benefits of influenza vaccinating in patients with cardiovascular diseases, as well as clinical experience from experts, this article proposes expert opinions on influenza vaccination in common cardiovascular diseases aiming to raise awareness of influenza prevention and benefiting patients.
